Hepatitis A vaccination in Iran: an evidence-to-recommendations synthesis using a WHO-aligned framework

Improved water, sanitation, and hygiene (WASH) have shifted hepatitis A virus (HAV) infection in Iran to older ages, when illness is more symptomatic and severe. Inactivated hepatitis A (HepA) vaccines are safe and effective, but Iran has no routine HepA vaccination; policy decisions must balance burden, economics, and feasibility. We conducted a Ministry of Health–commissioned evidence-to-recommendations (EtR) process integrating WHO (2022) and ACIP MMWR (2006/2020) guidance, Iranian sero-epidemiology, and evidence on burden, vaccine performance, cost-effectiveness, and implementation. Iran has transitioned to low endemicity: immunity is high among older adults, but susceptible cohorts remain among children, adolescents, and young adults, varying by province and socioeconomic strata. Available Iranian clinical data indicate that hepatitis A continues to cause clinically significant disease and hospitalization, although national estimates are limited; international evidence indicates greater severity among adults, particularly those with chronic liver disease or other comorbidities. Both licensed vaccine types, inactivated and live-attenuated, are highly effective and safe. The EtR panel considered both and based its recommendations on inactivated vaccines, because they are available in Iran, provide durable protection after 2 doses, and are suitable for immunocompromised persons, pregnant women, and PEP. Economic analyses generally support universal childhood vaccination mainly where incidence or outbreak risk is high; targeted vaccination is more favorable in low-endemic settings. Given Iran’s current epidemiologic profile, health-system context, and available economic evidence, while recognizing important gaps in national clinical and cost data, universal routine childhood vaccination was not prioritized; targeted vaccination and vaccine use for post-exposure prophylaxis (PEP) and outbreak control showed greater potential net benefit. EtR judgments support targeted HepA vaccination with inactivated vaccine for: (i) chronic liver disease and selected immunocompromising conditions; (ii) exposure-risk networks (e.g., drug use, homelessness, prisoners, some occupations); and (iii) outbreak, disaster, or humanitarian settings, alongside surveillance and PEP. Universal routine childhood vaccination is not supported at this time. Periodic reassessment is recommended as new sero-epidemiologic and economic data emerge.

Authors

Institutions

Publication Details

Journal
BMC Health Services Research
Published
2026-11-21
DOI
https://doi.org/10.1186/s12913-026-16182-7
Primary Topic
Hepatitis Viruses Studies and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatitis A vaccination in Iran: an evidence-to-recommendations synthesis using a WHO-aligned framework

Babak Eshrati, Ebrahim Babaee, Mona Roozbehani, Mahdi Roostaei et al.
BMC Health Services Research
Hepatitis Viruses Studies and Epidemiology
article

Hepatitis A vaccination in Iran: an evidence-to-recommendations synthesis using a WHO-aligned framework

Babak Eshrati, Ebrahim Babaee, Mona Roozbehani, Mahdi Roostaei, Mahdi Soheyli, Mahdi Hashempour
article en

Abstract

Improved water, sanitation, and hygiene (WASH) have shifted hepatitis A virus (HAV) infection in Iran to older ages, when illness is more symptomatic and severe. Inactivated hepatitis A (HepA) vaccines are safe and effective, but Iran has no routine HepA vaccination; policy decisions must balance burden, economics, and feasibility. We conducted a Ministry of Health–commissioned evidence-to-recommendations (EtR) process integrating WHO (2022) and ACIP MMWR (2006/2020) guidance, Iranian sero-epidemiology, and evidence on burden, vaccine performance, cost-effectiveness, and implementation. Iran has transitioned to low endemicity: immunity is high among older adults, but susceptible cohorts remain among children, adolescents, and young adults, varying by province and socioeconomic strata. Available Iranian clinical data indicate that hepatitis A continues to cause clinically significant disease and hospitalization, although national estimates are limited; international evidence indicates greater severity among adults, particularly those with chronic liver disease or other comorbidities. Both licensed vaccine types, inactivated and live-attenuated, are highly effective and safe. The EtR panel considered both and based its recommendations on inactivated vaccines, because they are available in Iran, provide durable protection after 2 doses, and are suitable for immunocompromised persons, pregnant women, and PEP. Economic analyses generally support universal childhood vaccination mainly where incidence or outbreak risk is high; targeted vaccination is more favorable in low-endemic settings. Given Iran’s current epidemiologic profile, health-system context, and available economic evidence, while recognizing important gaps in national clinical and cost data, universal routine childhood vaccination was not prioritized; targeted vaccination and vaccine use for post-exposure prophylaxis (PEP) and outbreak control showed greater potential net benefit. EtR judgments support targeted HepA vaccination with inactivated vaccine for: (i) chronic liver disease and selected immunocompromising conditions; (ii) exposure-risk networks (e.g., drug use, homelessness, prisoners, some occupations); and (iii) outbreak, disaster, or humanitarian settings, alongside surveillance and PEP. Universal routine childhood vaccination is not supported at this time. Periodic reassessment is recommended as new sero-epidemiologic and economic data emerge.

BMC Health Services Research
Iran University of Medical Sciences (IR), Tehran University of Medical Sciences (IR)
Hepatitis Viruses Studies and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon